AstraZeneca Brilinta (Tikagrelor) 90mg In Pakistan

AstraZeneca Brilinta (Tikagrelor) 90mg in Pakistan

Brilinta 90mg is a prescription antiplatelet medicine from AstraZeneca. Its active ingredient is ticagrelor (sometimes written as “Tikagrelor”). It belongs to the P2Y12 platelet-inhibitor class and works by reducing platelet activation, helping prevent harmful blood clots. Pakistan’s Drug Regulatory Authority documents also identify Brilinta 90mg as the AstraZeneca reference product containing ticagrelor.

Brilinta is a medication for people who have had a heart attack, and it’s been proven to significantly lower the risk of having another heart attack.

Ticagrelor

Ticagrelor is a blood-thinning tablet that helps keep your blood from forming sticky clumps that can block heart vessels. If you’ve had a heart issue or a stent placed, it works quietly in the background so blood can flow more freely and lower the chance of another scare.

• Take it exactly as directed, usually twice a day, with or without food.
• It can raise the risk of easy bruising or minor bleeding—be gentle with yourself and report big or unusual bleeding.
• Tell your care team about other medicines and if you plan any surgery.
• Skip grapefruit, and don’t stop the pill suddenly without asking.

Want help choosing what suits you? You can compare the best Ticagrelor brands in Pakistan or check the Ticagrelor price in Pakistan here. I’m happy to walk you through options so you feel confident about your pick.

Main Benefits & Uses

Brilinta may be prescribed to help:

• Reduce the risk of heart attack (myocardial infarction).
• Reduce the risk of cardiovascular death in appropriate patients with acute coronary syndrome (ACS).
• Reduce the risk of ischemic stroke in indicated patients.
• Reduce blood-clot formation inside a coronary stent after stent placement for ACS.
• In certain patients with coronary artery disease, reduce the risk of a first heart attack or stroke.

What Conditions Is It Used For?

Doctors may use ticagrelor in patients with acute coronary syndrome, including:

• Unstable angina
• NSTEMI
• STEMI
• Certain patients following coronary angioplasty/PCI and stent placement
• Selected patients with a previous heart attack

The exact indication and treatment duration depend on the patient's cardiovascular condition and bleeding risk.

How Brilinta 90mg Works

When a blood vessel is damaged, platelets can become activated and stick together to form a clot. Ticagrelor blocks the platelet P2Y12 receptor, reducing platelet activation and aggregation. This helps lower the likelihood of a dangerous clot forming in the coronary arteries or a coronary stent.

Dosage & Guidance

For ACS or a history of heart attack, the current U.S. prescribing information specifies an initial 180mg loading dose, followed by 90mg twice daily during the first year. After one year, the dose may be changed to 60mg twice daily when continued for appropriate patients. Treatment should be individualized by the treating physician.

Important: Do not start, stop, increase, or decrease Brilinta yourself. Stopping it prematurely can increase the risk of cardiovascular events, particularly in patients who have a coronary stent.

Important Safety Information

The most important risk with Brilinta is bleeding. It can cause significant, and in rare cases life-threatening, bleeding. Easy bruising, nosebleeds, or bleeding that takes longer to stop can occur.

Tell your doctor before taking Brilinta if you:

• Have active bleeding.
• Have previously had bleeding inside the brain.
• Have significant liver disease.
• Are scheduled for surgery or a dental procedure.
• Take aspirin, anticoagulants, NSAIDs, or other medicines that can increase bleeding.
• Are taking medicines that may interact with ticagrelor.

Brilinta should not be used in patients with active pathological bleeding or a history of intracranial hemorrhage, according to the prescribing information.

Common Side Effects

Possible side effects include:

• Bleeding or bruising
• Shortness of breath (dyspnea)
• Nosebleeds
• Other forms of bleeding

Shortness of breath is a recognized adverse effect of ticagrelor and is often self-limiting, but new or severe breathing difficulty should be discussed with a healthcare professional.

When to Seek Urgent Medical Attention

Seek urgent medical care for heavy or uncontrollable bleeding, vomiting blood, coughing blood, black/tarry stools, blood in urine, sudden severe headache, weakness/numbness, confusion, or other signs of serious bleeding.

Brilinta 90mg in Pakistan

Brilinta 90mg is the AstraZeneca reference product containing ticagrelor 90mg. Pakistan’s DRAP documents also reference Brilinta 90mg in relation to locally manufactured ticagrelor products and bioequivalence studies. Availability, registration status, packaging, and price can vary, so patients should obtain the medicine through a legitimate pharmacy and verify the pack and registration details.

Important: This information is for educational purposes and does not replace a cardiologist's or physician's prescription. Brilinta is a prescription blood-thinning/antiplatelet medicine, so the correct dose and duration must be determined for the individual patient.